Skip to main content

Topical Compounded Agents

Topical compounded creams combining amitriptyline, baclofen, gabapentin, ketamine, and lidocaine — alone or in multi-agent formulations — are widely prescribed for vulvodynia / provoked vestibulodynia, chronic pelvic pain, genital / perineal / rectal pain, and as adjuncts for Peyronie's-related discomfort, despite a thin evidence base dominated by retrospective series, case reports, and a single large placebo-controlled RCT that was negative for general chronic pain.[1][2] Compounded combinations are not FDA-approved; individual commercially manufactured lidocaine products have their own labeling. Genital permeability is a hypothesis for local delivery, but also a potential route for systemic toxicity, not proof that these compounds work better or are safe.[3][4]

For the related comparator classes, see Gabapentinoids, Tricyclic antidepressants, SNRIs, NSAIDs and analgesics, and Local anesthetics.

Why topical in the urogenital tract​

The rationale for multi-agent topical therapy is multimodal peripheral analgesia — blocking several nociceptor mechanisms simultaneously while aiming to limit systemic exposure; absorption depends on ingredients, vehicle, site, barrier integrity and amount applied:[4][5]

TargetAgentPeripheral effect
Voltage-gated Na⁺ channelsLidocaine, amitriptyline (local-anesthetic-like)Blocks action-potential generation at the nociceptor terminal
NMDA receptors on primary afferentsKetamineReduces peripheral sensitization and wind-up
α2δ subunit of voltage-gated Ca²⁺ channelsGabapentinReduces excitatory neurotransmitter release
Peripheral GABA-B receptorsBaclofenModulates nociceptor–immune-cell cross talk
Mast-cell stabilization / H1AmitriptylineDampens neurogenic inflammation in vestibular epithelium

Peripheral targets are proposed, but their relative clinical contribution has not been established for most compounds. Local delivery does not exclude systemic absorption, particularly on mucosa or damaged skin.[30][31][4]

The critical negative trial — Brutcher 2019​

Any discussion of compounded pain creams must be framed against the largest and most rigorous RCT performed to date.[1]

  • Design: three parallel placebo-controlled RCTs at a military treatment facility; n = 399 patients with localized chronic pain classified as neuropathic, nociceptive, or mixed
  • Formulations tested:
    • Neuropathic cream: ketamine + gabapentin + clonidine + lidocaine
    • Nociceptive cream: ketoprofen + baclofen + cyclobenzaprine + lidocaine
    • Mixed cream: ketamine + gabapentin + diclofenac + baclofen + cyclobenzaprine + lidocaine
  • Result: no difference vs placebo at 1 month for neuropathic pain (−0.1), nociceptive pain (−0.3), or mixed pain (−0.3)
  • Interpretation: the tested mixtures did not outperform vehicle; the trial argues against routine use for those pain populations

A Lancet review questioned the evidence for multi-agent creams; adding multiple ingredients does not itself establish a useful peripheral mechanism.[2]

The Brutcher study does not answer every genital-pain question, but a different application site is not evidence of efficacy. FDA’s NASEM assessment found limited efficacy evidence and inadequate safety data. An FDA-authored safety review identified 24 systemic adverse-event cases, including coma, seizures and hypotension; ten involved face or genital application and ten had absorption confirmed by testing. These reports identify possible harms, not their incidence.[30][31]

Individual agents — evidence for urogenital use​

Topical lidocaine — indication and comparator matter​

Lidocaine blocks voltage-gated sodium channels on peripheral nociceptors. It has randomized evidence for specific urogenital settings, with both positive and negative findings. A trial’s design level is not the same as a positive efficacy result.[5][6]

  • Zolnoun 2003 (prospective trial, n = 61): overnight 5% lidocaine ointment applied to the vestibule for a mean of 7 weeks — 76% of women reported ability to have intercourse (vs 36% before treatment; p = 0.002); intercourse-related pain fell by 39 points on a 100-mm VAS[6]
  • ACOG breast-cancer-survivor consensus 2021 — 4% aqueous lidocaine applied to the introitus for 3 min before intercourse reduced dyspareunia by 88% vs 38% placebo (double-blind RCT, n = 46)[7]
  • Foster 2010 (133 women): topical 5% lidocaine, oral desipramine and their combination did not significantly outperform placebo for the primary tampon-pain endpoint.[32]
  • Morin 2021 (212 women): multimodal physical therapy was superior to overnight 5% lidocaine for provoked vestibulodynia; intercourse pain differed by 1.8/10 after treatment (95% CI 1.2–2.3), with benefit sustained at six months. Much/very-much improvement was 79% versus 39%. This supports pelvic-floor therapy rather than assuming a cream is the preferred initial treatment.[33]
  • Vestibulodynia UPDATe (NCT03844412): completed, with 209 enrolled; results posted March 19, 2026. The factorial trial compared topical lidocaine/estradiol, oral nortriptyline, both and double placebo. Posted mixed-model comparisons across the four arms did not show significant differences for tampon-test pain (p=0.3630) or SF-MPQ pain change (p=0.9859). These are registry results, with paired pain data in 170 participants, not a peer-reviewed efficacy publication or proof of equivalence.[9][34]
  • Intravesical alkalinized lidocaine — AUA-recommended (Grade B) for IC/BPS; a small lidocaine–heparin combination trial reported relief through 12 hours; this is not an assured duration for every lidocaine regimen.[10][11] Covered separately in Local anesthetics and IC/PBS

Typical compounding: 2–5% in ointment (preferred for vestibular tolerance) or aqueous base.

Topical gabapentin​

Gabapentin binds the α2δ subunit of voltage-gated calcium channels on peripheral sensory terminals.[5]

  • Boardman 2008 (retrospective, n = 51) — topical gabapentin 2–6% to the vulva for ≥8 weeks: among 35 evaluable women, mean pain score 7.26 → 2.49 (Δ −4.77; p < 0.001); 28/35 (80%) achieved ≥50% pain improvement; 51 were treated, so this is not an 80% intention-to-treat response[12]
  • Ergisi 2023 narrative synthesis — 4 studies of topical gabapentin for vulvodynia all reported improvement, but all were uncontrolled; the review explicitly called for double-blind RCTs[13]
  • American Academy of Pain Medicine 2025 — "limited evidence from single observational studies suggests that gabapentin 6% might be effective for vulvodynia, burning pain, and itching"[3]

Do not conflate topical with oral. Brown 2018 (RCT, n = 89) showed oral extended-release gabapentin (1,200–3,000 mg/day) was not superior to placebo on tampon-test pain (adjusted mean 4.0 vs 4.3; p = 0.07) — a negative result that does not settle the topical question because tissue concentrations and off-target effects differ by route.[14]

Typical compounding: 2–6% in a cream or gel base.

Topical amitriptyline​

Acts through peripheral sodium-channel blockade, antihistaminic effects on mast cells (relevant to the neuroinflammatory model of vestibulodynia), and local serotonergic / noradrenergic receptor modulation. Systemic exposure cannot be assumed negligible, especially with mucosal application, high concentrations or penetration-enhancing vehicles.[30][31][5][15]

  • ACOG Committee Opinion 673 on persistent vulvar pain (2016) lists topical TCAs compounded into cream among commonly prescribed medications for vulvodynia[15]
  • Ruoss 2021 (single-clinic audit, n = 376 respondents) — amitriptyline 0.5% + oestriol 0.03% in an organogel applied to the vestibule: rated effective by 51–67% across age groups; stinging at application was the main adverse effect[16]
  • Vulvodynia State-of-the-Science review 2023 — amitriptyline cream and amitriptyline-with-baclofen cream showed pre-to-post pain reduction in non-RCT studies; randomized evidence is insufficient[8]

Typical compounding: 2–5% in a cream or organogel base.

Topical baclofen​

GABA-B agonist acting on peripheral receptors expressed on sensory terminals and resident immunocompetent cells in the vestibular epithelium. The mechanistic argument is explicitly one of modulating nociceptor–immune-cell–epithelial cell cross talk, not a requirement for transdermal delivery.[4]

  • Keppel Hesselink 2014 — case report of a 33-year-old woman with intractable vulvar and anal pain unresponsive to standard therapy; topical baclofen 5% + palmitoylethanolamide produced >50% symptom reduction at 3 months with return of pain-free intercourse[17]
  • AAFP dyspareunia review 2021 — "compounded muscle relaxants" listed among vulvodynia options (Level C)[18]

Typical compounding: 2–5% in a cream base.

Topical ketamine​

NMDA-receptor antagonist with additional peripheral sodium-channel and opioid-receptor activity at the high local concentrations achievable topically.[19][20]

  • Poterucha 2012 (Mayo Clinic, retrospective, n = 13) — topical amitriptyline-ketamine cream for genital, rectal, or perineal pain: 1 (8%) complete relief, 6 (46%) substantial, 4 (31%) some, 2 (15%) none — 85% overall response rate; only 1 patient reported occasional irritation; the small chart series cannot exclude systemic adverse effects. Diagnoses included vulvodynia, proctalgia fugax, coccydynia, pudendal neuralgia, and post-surgical perineal pain[21]
  • Cochrane 2025 — topical ketamine alone showed no clear evidence of benefit over placebo for chronic pain (low-certainty evidence); combination formulations were insufficiently studied[22]
  • AAPM 2025 — "small studies of topical ketamine alone did not find statistically significant benefit … smaller non-placebo-controlled trials of ketamine combined with amitriptyline and lidocaine found benefit for peripheral neuropathic pain"[3]
  • Sawynok 2014 — retrospective analyses of topical ketamine combinations show 40–75% response rates; controlled trials show benefit in only some outcomes; optimal dosing unclear[19]

Typical compounding: 2–10% in a cream or gel base. Undetectable levels in selected studies do not establish absence of exposure or toxicity for other formulations, doses or genital application sites.[31][20]

Reported formulations — not standard prescriptions​

FormulationReported concentrationsStudied use (often off-label)Evidence limitsReference
Lidocaine ointment (single-agent)5%Vulvodynia / vestibulodynia, dyspareuniaMixed RCT findings; PFPT superior in Morin trial[6][7][8]
Lidocaine + oestradiolLidocaine 5% + E₂ 0.02%Vestibulodynia (UPDATe)Completed UPDATe; posted primary pain comparisons not significant[9]
Gabapentin (single-agent)2–6%Vulvodynia, vestibular burningRetrospective 51 treated, 35 evaluable; 28 improved ≥50%[12]
Amitriptyline + ketamineAmitriptyline 2–5% + ketamine 2–5%Genital, rectal, perineal painRetrospective n = 13, 85% response[21]
Amitriptyline + oestriolAmitriptyline 0.5% + E₃ 0.03%Vulvodynia, pudendal neuralgiaClinic audit n = 376[16]
Amitriptyline + baclofenAmitriptyline 2% + baclofen 2–5%Vulvodynia / vestibulodyniaPre-post observational[8]
Baclofen + PEABaclofen 5% + PEA 1%Vulvodynia, proctodyniaCase reports[17]
Multi-agent (ABGKL)Amitriptyline 5% + baclofen 2% + gabapentin 5% + ketamine 5% + lidocaine 5%Chronic pelvic / genital painExpert opinion; no RCT for this combination[3]

Urologic applications​

Vulvodynia and provoked vestibulodynia — the primary indication​

  • ACOG lists commonly prescribed topical agents but also discusses the negative lidocaine trial; listing a medication does not establish it as effective first-line treatment[15]
  • AAFP 2021 / 2025 lists compounded gabapentin, compounded muscle relaxants, and amitriptyline among pharmacologic options (Level C)[18][23]
  • Vulvodynia Therapeutic Research Summit 2024 identified neuroinflammation-directed agents — ketotifen fumarate, resiniferatoxin, specialized pro-resolving mediators, luteolin, alpha-lipoic acid — as the highest-priority targets for future research. The traditional compounded agents (amitriptyline, baclofen, gabapentin, ketamine) were not among the top-ranked agents, signaling that the field expects to move beyond empiric multi-agent creams.[24]

Genital, rectal, and perineal pain​

The Mayo Clinic amitriptyline-ketamine series[21] is the most direct evidence — 11/13 reported some relief in a heterogeneous chart series. Selection, placebo effects and concomitant treatment limit interpretation; this does not establish an 85% expected response or reassuring systemic safety.

Chronic pelvic pain (CPP, CP/CPPS)​

No dedicated trials evaluate multi-agent compounded creams for CP/CPPS or female CPP as distinct from vulvodynia. The ACOG CPP Practice Bulletin (2020) recommends trigger-point injections for myofascial CPP (Level B); topical creams are used anecdotally as adjuncts to pelvic-floor physical therapy.[25][26]

Peyronie's disease​

Topical agents for PD are a distinct literature. The AUA PD guideline lists topical verapamil and liposomal rhSOD among investigational topical options.[27] A systematic review concluded that topical medications did not demonstrate consistent improvement across outcomes.[28] The H-100 gel (nicardipine + SOD + emu oil) showed a signal in a small acute-phase pilot RCT.[29] Multi-agent analgesic creams of the type discussed here are not first-line for PD and have no randomized evidence.

Practical use and safety​

Establish the pain diagnosis first. Vulvar dermatoses, infection, GSM, pelvic-floor myalgia and neuropathic pain require different treatment. Multimodal pelvic-floor physical therapy has stronger comparative evidence than routine escalation through compounded creams for provoked vestibulodynia.[15][33]

If an individualized topical trial is selected, document the exact ingredients, concentration, vehicle, measured amount, application site, frequency and stop/reassessment plan with the dispensing pharmacy. Published concentration ranges are not interchangeable prescriptions. A thin layer two or three times daily is not a safe universal instruction for every high-concentration mixture. Local burning may come from the vehicle or active drugs; stopping irritating products can itself help.[15][30]

Systemic toxicity remains possible. Avoid extrapolating intact-skin absorption data to genital mucosa or damaged skin. Review other local anesthetics and CNS-active drugs, prevent accidental child/partner exposure, and counsel about sedation, confusion, neurologic symptoms or cardiovascular symptoms requiring urgent assessment. Do not use high-strength combinations under occlusion without an explicit formulation-specific plan.[31]

When an appropriate licensed product can meet the need, consider it before a compounded mixture. Compounded products have not undergone FDA approval for safety, efficacy or quality; pharmacy oversight is not equivalent to product approval. Verify the patient’s actual cost and coverage rather than quoting a universal price.[30]

Evidence to carry into counseling​

  • Brutcher 399-person trial: no superiority of the tested compounded mixtures for localized chronic pain; genital applicability remains uncertain.[1]
  • Lidocaine: positive breast-cancer dyspareunia evidence is specific to selected vestibular pain; the vulvodynia placebo trial was negative and a larger comparative trial favored physical therapy.[7][32][33]
  • Gabapentin, amitriptyline, baclofen and ketamine creams: small uncontrolled reports do not establish a preferred sequence, reliable response rate or freedom from systemic harms.[8][12][21][31]
  • UPDATe: recruitment is complete and registry results are available; the posted primary pain comparisons do not justify presenting the combination as proven.[34]

See Also​

References​

1. Brutcher RE, Kurihara C, Bicket MC, et al. "Compounded topical pain creams to treat localized chronic pain: a randomized controlled trial." Ann Intern Med. 2019;170(5):309–318. doi:10.7326/M18-2736

2. Cohen SP, Vase L, Hooten WM. "Chronic pain: an update on burden, best practices, and new advances." Lancet. 2021;397(10289):2082–2097. doi:10.1016/S0140-6736(21)00393-7

3. Lawson E, Singla P, Adler J, et al. "Topical analgesics for neuropathic pain: an evidence-informed guide for the practicing clinician." Pain Med. 2025;pnaf130. doi:10.1093/pm/pnaf130

4. Keppel Hesselink JM, Kopsky DJ, Sajben N. "New topical treatment of vulvodynia based on the pathogenetic role of cross talk between nociceptors, immunocompetent cells, and epithelial cells." J Pain Res. 2016;9:757–762. doi:10.2147/JPR.S115407

5. Kocot-Kępska M, Zajączkowska R, Mika J, et al. "Topical treatments and their molecular/cellular mechanisms in patients with peripheral neuropathic pain — narrative review." Pharmaceutics. 2021;13(4):450. doi:10.3390/pharmaceutics13040450

6. Zolnoun DA, Hartmann KE, Steege JF. "Overnight 5% lidocaine ointment for treatment of vulvar vestibulitis." Obstet Gynecol. 2003;102(1):84–87. doi:10.1016/s0029-7844(03)00368-5

7. American College of Obstetricians and Gynecologists. "Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus." Obstet Gynecol. 2021;138(6):950–960. doi:10.1097/AOG.0000000000004601

8. Schlaeger JM, Glayzer JE, Villegas-Downs M, et al. "Evaluation and treatment of vulvodynia: state of the science." J Midwifery Womens Health. 2023;68(1):9–34. doi:10.1111/jmwh.13456

9. Carey ET, Geller EJ, Rapkin A, et al. "Rationale and design of a multicenter randomized clinical trial of vestibulodynia: understanding pathophysiology and determining appropriate treatments (Vestibulodynia: UPDATe)." Ann Med. 2022;54(1):2885–2897. doi:10.1080/07853890.2022.2132531

10. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

11. Parsons CL, Zupkas P, Proctor J, et al. "Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis." J Sex Med. 2012;9(1):207–212. doi:10.1111/j.1743-6109.2011.02542.x

12. Boardman LA, Cooper AS, Blais LR, Raker CA. "Topical gabapentin in the treatment of localized and generalized vulvodynia." Obstet Gynecol. 2008;112(3):579–585. doi:10.1097/AOG.0b013e3181827c77

13. Ergisi M, Law A, Chaudhari N, et al. "Effectiveness of topical gabapentin in the treatment of vulvodynia: a narrative synthesis." Front Pain Res. 2023;4:1159268. doi:10.3389/fpain.2023.1159268

14. Brown CS, Bachmann GA, Wan J, Foster DC. "Gabapentin for the treatment of vulvodynia: a randomized controlled trial." Obstet Gynecol. 2018;131(6):1000–1007. doi:10.1097/AOG.0000000000002617

15. American College of Obstetricians and Gynecologists. Persistent Vulvar Pain. Committee Opinion 673. 2016. Official guidance.

16. Ruoss CM, Howard EA, Chan K, Stevenson PG, Vancaillie T. "Topical treatment of vulvodynia, dyspareunia and pudendal neuralgia: a single clinic audit of amitriptyline and oestriol in organogel." Aust N Z J Obstet Gynaecol. 2021;61(2):270–274. doi:10.1111/ajo.13292

17. Keppel Hesselink JM, Kopsky DJ, Sajben NL. "Vulvodynia and proctodynia treated with topical baclofen 5% and palmitoylethanolamide." Arch Gynecol Obstet. 2014;290(2):389–393. doi:10.1007/s00404-014-3218-4

18. Hill DA, Taylor CA. "Dyspareunia in women." Am Fam Physician. 2021;103(10):597–604.

19. Sawynok J. "Topical and peripheral ketamine as an analgesic." Anesth Analg. 2014;119(1):170–178. doi:10.1213/ANE.0000000000000246

20. Kopsky DJ, Keppel Hesselink JM, Bhaskar A, et al. "Analgesic effects of topical ketamine." Minerva Anestesiol. 2015;81(4):440–449.

21. Poterucha TJ, Murphy SL, Rho RH, et al. "Topical amitriptyline-ketamine for treatment of rectal, genital, and perineal pain and discomfort." Pain Physician. 2012;15(6):485–488.

22. Ferraro MC, Cashin AG, Visser EJ, et al. "Ketamine and other NMDA receptor antagonists for chronic pain." Cochrane Database Syst Rev. 2025;8:CD015373. doi:10.1002/14651858.CD015373.pub2

23. Dalrymple SN, Hoeg L, Thacker H. "Female sexual dysfunction: common questions and answers." Am Fam Physician. 2025;111(5):433–442.

24. Krapf JM, Yong PJ, Berke MD, et al. "Executive summary of the Vulvodynia Therapeutic Research Summit." Obstet Gynecol. 2025. doi:10.1097/AOG.0000000000006118

25. American College of Obstetricians and Gynecologists. "Chronic pelvic pain: ACOG Practice Bulletin, Number 218." Obstet Gynecol. 2020;135(3):e98–e109. doi:10.1097/AOG.0000000000003716

26. Namazi G, Chauhan N, Handler S. "Myofascial pelvic pain: the forgotten player in chronic pelvic pain." Curr Opin Obstet Gynecol. 2024;36(4):273–281. doi:10.1097/GCO.0000000000000966

27. Nehra A, Alterowitz R, Culkin DJ, et al. "Peyronie's disease: AUA guideline." J Urol. 2015;194(3):745–753. doi:10.1016/j.juro.2015.05.098

28. Hayat S, Brunckhorst O, Alnajjar HM, et al. "A systematic review of non-surgical management in Peyronie's disease." Int J Impot Res. 2023;35(6):523–532. doi:10.1038/s41443-022-00633-w

29. Twidwell J, Levine L. "Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study." Int J Impot Res. 2016;28(2):41–45. doi:10.1038/ijir.2015.22

30. US FDA. NASEM Assessment on the Safety and Effectiveness of Ingredients Used in Compounded Topical Pain Creams. 2020. FDA assessment.

31. Kim J, Konkel K, Jones SC, McCulley L. Systemic adverse events associated with compounded topical pain products. Drug Saf. 2020;43:497–501. doi:10.1007/s40264-020-00927-2.

32. Foster DC, Kotok MB, Huang LS, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol. 2010;116:583–593. doi:10.1097/AOG.0b013e3181e9e0ab.

33. Morin M, Dumoulin C, Bergeron S, et al. Multimodal physical therapy versus topical lidocaine for provoked vestibulodynia: a multicenter, randomized trial. Am J Obstet Gynecol. 2021;224:189.e1–189.e12. doi:10.1016/j.ajog.2020.08.038.

34. ClinicalTrials.gov. Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments (UPDATe). NCT03844412. Completed; results posted March 19, 2026. Registry results. Accessed September 12, 2026.